Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Axitinib (Inlyta™)

Last Updated: 02/16/18

Status: Currently a NF2 Clinical Trial

Chemical Structure, Axitinib
Synonyms: Axitinib, Inlyta, 319460-85-0, AG-013736, AG 013736,
UNII-C9LVQ0YUXG, AG013736, S1005_Selleck,
AG-013736, AG-13736
Trade Name: Inlyta™
Pharmaceutical Company Pfizer
Legal Status: ℞ - Prescription/Under Clinical Trial
Treatment By: Pill - Oral
Tumor Target: Vestibular Schwannoma
Protein Target: TKI and VEGF Inhibitor
NF2 Trials: Recruiting Trial: NCT02129647
Formula: C22H18N4OS
ChemSpider: 4953153
PubChem: CID 6450551


  • Drinking extra water or diluted fluids as well as avoiding fatty, fried, spicy, or highly sweet foods can help with many of the potential side effects.
  • Take Axitinib at night instead of the morning to prevent fatigue.

Other Known Uses

  • Breast Cancer
  • Renal Cell Carcinoma (RCC)
  • In Research for: Mesothelioma

Side Effects

  • High Blood Pressure / Nosebleeds
  • Diarrhea
  • Fatigue / Tiredness
  • Decrease in Appetite
  • Nausea / Vomiting
  • Hoarseness / Dry Thrroat
  • Skin Conditions - Dry Skin and Blisters
  • Constipation


  1. Petrilli, Alejandra M., et al. "Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells." Oncotarget 8.19 (2017): 31666.
    Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458238/ | DOI: 10.18632/oncotarget.15912

  2. Reveal, AI-Enabled Phenotypic Screens. "Clinically Relevant Drugs." (2012)
    Source: https://recursionpharma.com/wp-content/uploads/2017/09/AI-Enabled_Pheno-9_25_2017v24.pdf

  3. Meric-Bernstam, Funda, et al. "A decision support framework for genomically informed investigational cancer therapy." Journal of the National Cancer Institute 107.7 (2015): djv098.
    Source: https://academic.oup.com/jnci/article/107/7/djv098/913288 | DOI: 10.1093/jnci/djv098

  4. Karajannis, Matthias A., and Rosalie E. Ferner. "Neurofibromatosis-related tumors: emerging biology and therapies." Current opinion in pediatrics 27.1 (2015): 26.
    Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374132/ | DOI: 10.1097/MOP.0000000000000169

  5. Shaw, Adam. "Diagnosis and Management of Hereditary Meningioma and Vestibular Schwannoma." Rare Hereditary Cancers. Springer, Cham, 2016. 17-27.
    Source: https://link.springer.com/chapter/10.1007/978-3-319-29998-3_2 | DOI: 10.1007/978-3-319-29998-3_2
    Widemann, Brigitte C., and Scott R. Plotkin. "Consensus for NF clinical trials Recommendations of the REiNS collaboration (Supplement II)." (2016): S1-S3.
    Source: https://link.springer.com/chapter/10.1007/978-3-319-29998-3_2 | DOI: